Compound profile
Also known as: Copper peptide · glycyl-L-histidyl-L-lysine copper
A copper-binding tripeptide studied in skin biology and remodeling. Appears in topical cosmetic research and in online discussions of recovery and tissue quality.
GHK-Cu is a small, naturally occurring peptide made of three amino acids, glycine, histidine, and lysine, bound to a copper ion. Biochemist Loren Pickart first isolated it from human plasma in 1973 after noticing that older plasma samples had lower levels of the peptide-copper complex than younger ones, which helped set the research agenda that followed: GHK-Cu as a signal that declines with age and is involved in how the body maintains and repairs tissue.
The peptide's largest and most established body of research sits in dermatology and cosmetic science, where topical formulations, creams and serums, have been tested in human studies for effects on skin appearance. That is a different context from the injectable, systemic use discussed in some online research-peptide communities, where the evidence is far thinner and mostly extrapolated from cell and animal work rather than direct human trials.
Because of its cosmetic-industry roots, GHK-Cu is easy to find as an over-the-counter skincare ingredient, which is a separate regulatory lane from the injectable research-chemical vials sold for systemic use. The two forms share a name but should not be treated as equivalent.
Proposed to influence gene expression related to remodeling, antioxidant defense, and extracellular matrix. Copper complexation is central to many mechanistic hypotheses.
GHK-Cu's biology is closely tied to its copper. Copper is a required cofactor for lysyl oxidase and lysyl hydroxylase, two enzymes that cross-link collagen fibers and give connective tissue its strength, so delivering copper in this chelated, bioavailable form is central to most proposed mechanisms. Research describes GHK-Cu acting on gene expression tied to tissue remodeling, prompting cells to both build and break down collagen and glycosaminoglycans in a more balanced, regulated way rather than simply adding bulk collagen.
Studies also describe it modulating matrix metalloproteinases (MMPs) and their natural inhibitors, a balance that matters for how well a wound remodels instead of scarring. Separately, lab work has reported antioxidant and anti-inflammatory activity, and in irradiated cell models, GHK-Cu treated fibroblasts showed growth patterns and growth factor secretion, including basic fibroblast growth factor and VEGF, closer to healthy, non-irradiated cells. Most of this mechanistic picture comes from cell culture and animal research, with topical human studies focused mainly on downstream appearance outcomes rather than confirming the underlying pathway directly.
Cosmetic and dermatology literature includes human topical studies on appearance metrics. Systemic injectable claims popular online are far less supported than topical skin research.
What studies, case reports, and the research literature describe, not guaranteed outcomes. The trials behind these findings are in the studies below.
Human topical studies report improvements in fine lines, skin laxity, and photodamage-related appearance measures with regular use.
Lab research reports increased synthesis of collagen, elastin, and glycosaminoglycans, alongside more regulated turnover of the extracellular matrix.
Animal studies describe faster wound closure, improved skin-graft integration, and increased blood vessel formation at injury sites.
Cell and animal research report reduced markers of oxidative stress and calming effects on inflamed tissue.
Route of administration matters: topical evidence does not validate systemic research-chemical narratives. Copper load and product quality are practical concerns. Separate marketing claims from peer-reviewed endpoints.
Route of administration is the key thing to separate out here. The strongest, most human-relevant evidence for GHK-Cu is topical, cosmetic studies measuring skin appearance, not systemic injection. Claims about injectable GHK-Cu for broader recovery or anti-aging are extrapolated from that topical and preclinical work, and no published human clinical trial has directly evaluated the safety of injected GHK-Cu. Some analyses estimate the copper dose in typical research protocols sits far below levels associated with toxicity, but that estimate has not been confirmed in rigorous human injectable studies, and case-report level data suggest injection-site irritation is the most commonly described issue. As with other unregulated research peptides, product purity and manufacturing quality are a separate risk from the biology of the molecule itself.
Start with our in-house roundups, plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
Commonly discussed together
Online communities often discuss GHK-Cu, BPC-157, and TB-500 together under the informal name “GLOW,” usually in the context of skin quality and soft-tissue recovery conversations, not as a single studied product.
GLOW is a community nickname, not a validated clinical protocol. There are no dose schedules here. Read each peptide’s evidence level and primary sources separately.
Skin / repair · Recovery
